Problems in dealing with very rare adverse effects of new anticancer drugs: The example of trabectedin

Tumori

Volumn 97, Issue 2, 2011, Pages 256-

  Grosso, Federica ^a   D'Incalci, Maurizio ^b  

^a SC Oncologia   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; TRABECTEDIN;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; CONVALESCENCE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FUNCTIONAL STATUS; HUMAN; LEIOMYOSARCOMA; LETTER; LIVER CLEARANCE; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; OVARY CANCER; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOFT TISSUE SARCOMA; UTERUS SARCOMA;

EID: 79957634768     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700224     Document Type: Letter

References (2)

1. Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N: Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori, 97: 252-255, 2011.
2. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer, 42: 1484-1490, 2006. (Pubitemid 43903160)